| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/03/2002 | US20020001589 Complex of lipooligosaccharide and immunology carriers |
| 01/03/2002 | US20020001585 Administering a blocking agent of tumor necrosis factors or receptors; treatment of Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue viral disease |
| 01/03/2002 | US20020001576 Medicaments containing allogenic activated-CD4+ cells as the main ingradient, which are attributable to an organ or bone marrow implant donor, have extreemly beneficial effect for preventing tumor and various infections |
| 01/03/2002 | US20020001567 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2783274A1 Vaccine composition |
| 01/03/2002 | CA2415238A1 Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
| 01/03/2002 | CA2415236A1 Novispirins: antimicrobial peptides |
| 01/03/2002 | CA2414512A1 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 01/03/2002 | CA2414308A1 Transport peptides derived from erns protein, cytotoxic rnase of ribosome-inactivating protein or a rsv g-protein and analogues thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2414089A1 Improvements in and relating to chromophores |
| 01/03/2002 | CA2413786A1 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413543A1 Human papilloma virus treatment |
| 01/03/2002 | CA2413336A1 Synthesis of cyclic compounds |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412621A1 Rescue of canine distemper virus from cdna |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412559A1 Polycyclic xanthones as antibiotics |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2411714A1 Novel cephalosporin compounds and process for preparing the same |
| 01/03/2002 | CA2411545A1 Tripeptide prodrug compounds |
| 01/03/2002 | CA2411162A1 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/03/2002 | CA2411157A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/02/2002 | EP1167386A1 Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167376A1 Macrolide antibiotics |
| 01/02/2002 | EP1167375A1 Erythromycin derivatives |
| 01/02/2002 | EP1166797A1 Method of controlling the qualities of attenuated pox vaccine |
| 01/02/2002 | EP1166794A2 Method of treating retained pulmonary secretions |
| 01/02/2002 | EP1166782A2 Anti-retroviral pharmaceutical compositions |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165796A2 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| 01/02/2002 | EP1165795A2 Streptococcus pneumoniae antigens |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165772A1 Protein-protein complexes from s. cerevisiae and methods of using same |
| 01/02/2002 | EP1165756A2 Adaptation of virus to vertebrate cells |
| 01/02/2002 | EP1165614A1 Antibodies against phosphomannan that are protective against candidiasis |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165597A1 Bifunctional molecules for delivery of therapeutics |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165565A1 Optically pure camptothecin analogues |
| 01/02/2002 | EP1165564A2 Process for preparing inhibitors of nucleoside metabolism |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165560A1 2-hydroxy methylcyclopro pylidenemethyl purines and -pyrimidines as antiviral agents |
| 01/02/2002 | EP1165559A1 1,4-diazabicyclo 3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165541A1 Dimeric compounds and as inhibitors of neuraminidase |
| 01/02/2002 | EP1165532A1 Antibacterial agents |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165494A2 Hsv primase inhibitors |
| 01/02/2002 | EP1165492A1 Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165140A2 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/02/2002 | EP1165132A2 Dry formulation for transcutaneous immunization |
| 01/02/2002 | EP1165131A2 Attenuated dengue-1 virus vaccine |
| 01/02/2002 | EP1165130A2 Attenuated dengue-3 virus vaccine |
| 01/02/2002 | EP1165129A1 Attenuated dengue-4 virus vaccine |
| 01/02/2002 | EP1165128A2 Attenuated dengue-2 virus vaccine |
| 01/02/2002 | EP1165127A2 Multivalent dengue virus vaccine |
| 01/02/2002 | EP1165126A1 Human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 01/02/2002 | EP1165120A2 A uro-genital condition treatment system |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165094A1 Dispersible macrolide compounds and method for the production thereof |
| 01/02/2002 | EP1165092A1 Cyclopentanone derivatives and their use |
| 01/02/2002 | EP1165091A1 Pharmaceutical emulsions for retroviral protease inhibitors |
| 01/02/2002 | EP1165089A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies |
| 01/02/2002 | EP1165084A1 Inhibitors of prenyl-protein transferases |
| 01/02/2002 | EP1165082A1 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1165080A2 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 01/02/2002 | EP1165077A2 Viral treatment |
| 01/02/2002 | EP1165074A2 Viral treatment |
| 01/02/2002 | EP1165073A1 Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
| 01/02/2002 | EP1165070A1 Thiadiazolyl urea or thiourea derivatitives for antiviral treatment |
| 01/02/2002 | EP1165064A2 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 01/02/2002 | EP1165058A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 01/02/2002 | EP1165057A2 Endodontic fibers and methods of use therefor |
| 01/02/2002 | EP1165054A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 01/02/2002 | EP1165046A1 Propofol compositions containing preservative additives |
| 01/02/2002 | EP1165043A1 Drinkable pharmaceutical solution |
| 01/02/2002 | EP1165013A2 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1164991A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 01/02/2002 | EP1164874A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP1001801B1 Product comprising at least a double stranded rna combined with at least an interferon for the treatment of viral hepatitis |
| 01/02/2002 | EP0958307B1 O-sulfated bacterial polysaccharides |